TELO TELOMIR PHARMA
-
TELOMIR PHARMA Reported Earnings
Thursday, August 13, 2026 · 12:00 AM ET
TELOMIR PHARMA (TELO) reported a loss of $0.79 per share on revenue of $0.00 million for the . .
Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.79)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—